Growth Hormone Peptides

• GHRH Analog with DAC: 30-amino acid peptide with albumin-binding technology, ≥98% purity
• Extended Half-Life: 5.8-8.1 day biological half-life via maleimide-albumin conjugation
• GH/IGF-1 Axis Research: Sustained 2-10 fold GH and 1.5-3 fold IGF-1 elevation studies

Ipamorelinis a synthetic pentapeptide growth hormone secretagogue that selectively binds the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. In experimental models, Ipamorelin activates Gq/PLC-dependent calcium signaling pathways that stimulate growth hormone release while demonstrating minimal activity on other pituitary hormones, including ACTH, prolactin, FSH, LH, TSH, and cortisol. Due to its high receptor selectivity, Ipamorelin is widely utilized in rese

• 29-amino acid synthetic polypeptide representing biologically active N-terminal fragment of human GHRH
• FDA-approved 1990 (diagnostic) and 1997 (therapeutic) for pediatric GH deficiency; stimulates physiological pulsatile GH release via GHRH-R Gs-cAMP-PKA signaling
• Extensively validated in clinical trials spanning growth disorders, aging research, cognitive function, and body composition management

Sermorelin (GHRH(1-29)-NH₂) is a 29-amino acid synthetic fragment of human growth hormone-releasing hormone with C-terminal amidation. FDA-approved (1991 diagnostic, 1997 therapeutic), it activates pituitary GHRH-R via Gs-cAMP-PKA signaling while preserving physiological pulsatile GH secretion and somatostatin feedback regulation.

Tesamorelin is a 44-amino acid synthetic GHRH analog with N-terminal trans-3-hexenoic acid modification conferring DPP-IV resistance and extended half-life (26-38 minutes vs. 2 minutes for native GHRH). FDA-approved (2010) as Egrifta for HIV-associated lipodystrophy. Selectively activates pituitary GHRH receptors via Gs-cAMP-PKA signaling, stimulating pulsatile GH release while preserving IGF-1 feedback regulation.

• Synthetic GHRH Analog: 44-amino acid polypeptide with N-terminal trans-3-hexenoic acid modification, enhanced DPP-IV resistance, 26-38 min half-life vs. minutes for native GHRH, 150+ publications
• Physiological GH Axis Modulation: Selective GHRH-R agonist preserving pulsatile GH secretion patterns, 15.2% VAT reduction at 26 weeks, IGF-1 feedback regulation intact, no continuous GH elevation
• Clinical Status: FDA-approved Egrifta (2010) for HIV-associated lipodystrophy, Egrifta WR (F8 formulation, March 2025) weekly reconstitution, ongoing research in neurocognitive function/hepatic fat